Skip to content

Details

Come and join our open CEOs panel of successful BioMed companies!
The Panel will be led by Prof. Chezy Barenholz ( CEO of Ayana Pharma) and include 4 top CEOs:

  1. Mr. Amir Weisberg - CEO PolyPid. Since 2010, he leads the company and he has 20 years of experience as an entrepreneur and CEO of start-up companies with two financial exits. Prior to PolyPid, Mr. Weisberg managed start-up companies in the Life Science sphere, from incubator stage to clinical trials, including leading the financing rounds for these companies.

  2. Dror Ben-Asher, the Co-Founder and CEO of RedHill Biopharma, a U.S. – focused specialty pharmaceutical company, was previously with a European corporate finance firm. He completed his studies at the University of Oxford and Harvard University, where he was also a Fulbright Scholar focusing on the pharmaceutical industry and markets, an Olin Fellow for Law, Economics and Business, and an Economics Teaching Fellow at Harvard’s Economics Department.

  3. Professor Yanay Ofran, the founder and CEO of Biolojic Design, a biotech company that uses AI to design novel biological drugs; the cofounder (2016) and chairman of Ukko, a biotech company that uses protein deign to solve food allergies and sensitivities; and the cofounder (2020) and CEO of Aulos Bioscience, that develops computationally designed immuno-oncology therapeutics. Prof. Ofran, is the author of over 70 papers and patents.

  4. Dr. Roni Mamluk, founder and CEO of Ayala Pharma.
    Roni Mamluk is a senior biopharmaceutical executive with 16 years of experience in drug development companies and background in all aspects of R&D, general management and fundraising. Prior to Ayala, Roni was at Chiasma (NASDAQ: CHMA), a biopharmaceutical company focused on orphan diseases where she fulfilled multiple positions including CEO (2013-2015). She is an inventor of their oral delivery technology and led the development of their lead product through all stages of development, including NDA submission. She was a key player in fundraising for the company, including several private financing rounds and led a $70 million crossover financing and a successful IPO of over $100 million in 2015. Roni is now a board member at Chiasma. Prior to that, she was heading preclinical development of an oncology product at Adnexus (which was later acquired by Bristol-Myers Squibb (NYSE:BMY)) in Waltham, MA and did her post-doc at Children’s Hospital/Harvard Medical School in the field on angiogenesis prior to that. Roni received her PhD, summa cum laude from the Hebrew University in Jerusalem.

***The Zoom link for the event will be sent to the participants few days before the lecture after short, sample and free registration at: https://lnkd.in/dEpHaHi

Members are also interested in